Rituximab for the treatment of relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma

  • Technology appraisal guidance
  • TA137
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence